Category: 3. Business

Story Continues

There are growing fears of an imminent stock market crash – one that will transform from a dip to a dive when euphoric headlines about the wonders of artificial intelligence begin to wane.

Shares in US tech stocks have fallen in recent weeks and the prospect is that a flood of negative numbers will become the norm before the month is out.

It could be 2000 all over again, and just like the bursting of the dotcom bubble it may be ugly, with investors junking businesses that once looked good on paper but now resemble a huge liability.

Jerome Powell, the Federal Reserve chair, is one of the policymakers tasked with keeping the wolf from the door. Speaking on Friday at the annual Jackson Hole gathering of central bank governors in Wyoming, he tried to calm nerves.

He said the Fed was concerned about rising inflation, while at the same time willing to help an economy dogged by uncertainty induced by Donald Trump and a global economic slowdown.

With stagflation a genuine prospect – as the US economy slows and inflation remains high – Powell gave stock markets a sign that interest rates will fall, easing the pressure on indebted companies.

Stock markets are on Powell’s radar even more than usual now that so many personal pensions in the US are directly invested in listed companies. And, more particularly, tech stocks making huge AI investments that have yet to make a dollar of profit.

A recent Massachusetts Institute of Technology report revealed that 95% of companies investing in generative AI have yet to see any financial returns.

This revelation came after Sam Altman, the boss of the ChatGPT owner OpenAI, warned that some company valuations were “insane”.

Ipek Ozkardeskaya, a senior analyst at the currency trading firm Swissquote, said: “The [Altman] comments may have been a wake-up call for investors, sparking a sharp pullback in high-flying names.”

At the beginning of the week, the share price of the data mining and spyware firm Palantir, which has billions of dollars worth of US government contracts, plunged almost 10%. The AI chip maker Nvidia fell more than 3%, while other AI-linked stocks such as Arm, Oracle and AMD also lost ground.

Most pension funds will be invested in these tech companies, alongside more longstanding names such as Amazon, Microsoft, Alphabet (Google) and Meta (Facebook).

Should fund managers pull out? That would probably be unwise.

The scale of investment in AI by the likes of Google and Meta is vast and while the technology’s potential is the subject of much speculation, white-collar workers are becoming more familiar with the supposed benefits with every passing day.

Corporate messages asking them to use AI for presentations, report writing and research are a daily occurrence (accompanied, of course, with hollow assurances that job cuts are not being considered).

skip past newsletter promotion

after newsletter promotion

Microsoft’s Copilot and the many other “helpful” AI tools on offer are becoming embedded in office life and beginning to perform large numbers of low-level tasks.

If this trend takes off, and in many parts of the economy it already has, there is a soft landing waiting for the tech industry even as some of the flakier, more speculative businesses are weeded out and fail.

If anything, a downturn helps the big firms pick up new technological breakthroughs from the wreckage and on the cheap.

Palantir’s price-to-earnings ratio is north of 500 when most investors would find themselves getting panicky at anything above 50. Nvidia has a price-to-earnings ratio of 56.

The Palantir/Nvidia ratios could decline as their share price falls more into line with a reasonable prospect of likely earnings, but the businesses are not going to go bust, even in the most severe equity market storms.

Trump is another significant supporter, clearing the path for AI to make even deeper inroads into corporate life. His support for cryptocurrencies, including his own, and deregulated social media platforms, including his own, are indications of where his sympathies lie.

AI is probably going to be bad for humanity, given that politicians and regulators are light years behind the tycoons and tech magnates backing AI, many of whom see it as a new way to disempower and dominate workers.

However, as an investor, AI isn’t going away, crash or no crash.

Welcome to The Brink. This is Giulia Morpurgo and Constantine Courcoulas in London, where we looked at turmoil in the wind industry. We also have news on Rent the Runway and Greek GDP warrants. Follow this link to subscribe. Send us feedback and tips at debtnews@bloomberg.net.

Orsted’s capital increase and the bankruptcy of TPI Composites — announced in the matter of hours last week — echoed widely among wind energy investors as the sector grapples with President Donald Trump’s attacks, rising costs and competition from Chinese manufacturers.

US government debt could reach 250% of gross domestic product without putting upward pressure on interest rates, according to a paper presented at the Federal Reserve’s Jackson Hole conference.

“Until fiscal consolidation occurs, there will be a race between the rising asset demand of an older population and the rising debt issuance needed to finance the associated increase in government expenditures,” said its authors — Adrien Auclert of Stanford University, Hannes Malmberg of the University of Minnesota, Matthew Rognlie of Northwestern University and Ludwig Straub of Harvard University.

Another driver of demand is safety. Hands-free calling, integrated voice commands, and clear visual displays are no longer seen as extras but as necessary safeguards against distraction. Consumers actively search for affordable ways to align with modern driving standards, and Drivio Play delivers a solution without dealership markups.

Budget concerns also fuel this shift. The cost of new cars has soared, and financing options often stretch household budgets to the limit. By contrast, a compact upgrade like Drivio Play introduces premium features without the long-term financial burden of a new car loan. This balance of affordability and convenience is a key reason why the market for retrofit technology is one of the fastest growing automotive segments in 2025.

For drivers who value both safety and convenience, the search for smarter tech is no longer optional—it is expected. Drivio Play reflects this trend by transforming outdated dashboards into connected control centers for modern travel.

See why drivers are choosing Drivio Play in 2025

Key Features That Make Drivio Play Stand Out

The success of any car technology upgrade comes down to the features it delivers. In the case of Drivio Play, its design focuses on simplicity, compatibility, and performance. Drivers are not looking for complicated installation or hard-to-navigate menus—they want an intuitive system that works the moment it is powered on.

One of the most discussed features is seamless smartphone integration. Whether you rely on iOS or Android, Drivio Play connects quickly, allowing access to navigation, calls, and media without delay. This compatibility ensures that drivers do not have to change their habits or upgrade their devices to enjoy modern features.

Another highlight is its built-in display clarity. Unlike outdated aftermarket systems, Drivio Play provides sharp visuals that make navigation easier, especially on longer drives. The clear interface reduces confusion and keeps attention focused where it belongs—on the road.

Voice-command functionality is also central. As safety remains a top priority, Drivio Play supports hands-free control, so drivers can take calls, change tracks, or pull up directions without taking their hands off the wheel. This practical integration brings everyday convenience while reducing distraction risk.

Portability and universal design add to its appeal. Unlike dealer-installed systems tied to one car, Drivio Play can be moved between vehicles, making it a flexible choice for families with multiple cars or individuals who change vehicles frequently.

Durability rounds out the package. Built to withstand daily use, Drivio Play is designed for consistent performance across both short commutes and long-distance travel. This combination of adaptability, clarity, and resilience is why drivers highlight it in 2025 automotive conversations.

Explore the full range of Drivio Play features here

How Drivio Play Saves Drivers Money in 2025

One of the strongest reasons consumers are turning to Drivio Play in 2025 is financial practicality. Vehicle prices have climbed to record highs, leaving many households unwilling to commit to costly dealership upgrades or long-term financing. Instead, people are searching for affordable ways to make their existing cars smarter, safer, and more enjoyable to drive.

Drivio Play enters this conversation as a cost-effective alternative. Instead of replacing a car to gain advanced infotainment, navigation, or wireless streaming, drivers can install this device at a fraction of the cost. For families, this means keeping reliable vehicles on the road longer without sacrificing access to modern features.

Fuel savings also connect to the product’s value. With real-time navigation and traffic data available through connected apps, drivers can plan more efficient routes and reduce wasted fuel. Over time, these savings compound, making Drivio Play not just a tech upgrade but also a financial tool for smarter driving.

Another cost advantage is its portability. Unlike permanent installations, Drivio Play can move from one vehicle to another. This flexibility eliminates the need to buy multiple systems or pay for expensive dealer-specific hardware. Households with more than one car especially value this feature, as it stretches the utility of a single purchase.

By combining affordability, portability, and efficiency, Drivio Play allows drivers to access the technology they want without stretching their budgets. It represents a smarter way to upgrade, proving that financial caution and modern convenience can go hand in hand.

Safety and Convenience Benefits Drivers Value Most

Modern drivers want more than entertainment—they want tools that make every trip safer and easier. This is one of the reasons Drivio Play is gaining attention in 2025. It blends convenience with real-world safety features that respond to the demands of today’s road conditions.

Hands-free calling is one of the most practical benefits. With Drivio Play, drivers can take calls or send voice commands without handling a phone. This reduces distraction, aligning with the growing focus on safer driving practices.

Navigation support is another advantage. Clear display visuals combined with real-time map access mean fewer wrong turns and faster route adjustments when traffic shifts. Families and commuters alike value how this feature saves time and lowers stress behind the wheel.

Entertainment integration adds to convenience. Music streaming, podcasts, and audiobook playback all become accessible in seconds, helping transform long commutes into smoother experiences. Drivers appreciate that these features work seamlessly with both iOS and Android devices.

For many households, the ability to consolidate these functions into a single device eliminates clutter and improves overall driving confidence. Instead of juggling multiple gadgets, Drivio Play centralizes everything into one clear interface, giving drivers what they need without unnecessary complication.

By focusing on both safety and convenience, Drivio Play positions itself as more than an upgrade—it becomes an essential travel companion for everyday life.

See the safety and convenience benefits of Drivio Play here

Who Should Consider Drivio Play in 2025

The appeal of Drivio Play stretches across a wide range of drivers. While originally viewed as a simple aftermarket upgrade, it has quickly become relevant for households, commuters, and even tech adopters who want smarter travel without overpaying for a new car.

Families are among the strongest adopters. Parents often look for safer, distraction-free tools that keep them focused while transporting children. Features like voice command, navigation, and easy entertainment access make Drivio Play a reliable solution for busy households balancing safety with convenience.

Commuters also gravitate toward the device. Spending hours on the road each week means drivers want efficiency and comfort. With Drivio Play, they gain tools that simplify daily routes, improve connectivity, and make long drives less stressful.

Road trip enthusiasts and travelers find unique value too. Portability ensures that the system can be used across multiple vehicles, meaning families can bring the same connected experience whether driving their own car, a rental, or even sharing vehicles within a household.

Tech adopters form another segment of interest. This group enjoys trying modern gadgets that make daily life easier. For them, Drivio Play represents an opportunity to modernize an older car quickly, showing how technology can extend value from an existing vehicle.

Finally, cost-conscious households consider Drivio Play a practical investment. Rather than financing expensive new vehicles, they choose an affordable option that introduces current features without long-term debt.

In short, Drivio Play serves multiple audiences—from families to commuters to tech-focused drivers—by providing affordable connectivity that matches modern expectations.

How Drivio Play Compares to Dealership Installs

For many drivers, the decision to upgrade technology comes down to a choice between expensive dealership installations or practical aftermarket solutions. Drivio Play offers a clear alternative that avoids the high costs and limitations often tied to dealer systems.

Dealership upgrades can cost thousands of dollars and are usually restricted to the specific vehicle where they are installed. Once in place, they cannot be transferred, meaning drivers must pay again if they switch cars. By contrast, Drivio Play provides a portable option that can move between vehicles, making it a far more flexible investment.

Another difference lies in installation. Dealership systems often require professional setup, which means additional labor charges and long waiting times. Drivio Play is designed for quick, consumer-friendly setup, allowing most users to begin using the system without paying extra fees.

Functionality is also broader with Drivio Play. While dealership systems are tied to manufacturer updates, this device integrates seamlessly with both Android and iOS, giving users consistent access to navigation, music, and voice commands. This flexibility ensures that drivers do not lose features as technology evolves.

Maintenance is another factor. If a dealership-installed unit fails, drivers must return to the dealer for costly repairs or replacements. With Drivio Play, the process is simpler, affordable, and does not tie drivers to dealership contracts.

When comparing affordability, adaptability, and ease of use, Drivio Play emerges as the smarter option for households that want modern driving features without unnecessary financial strain.

The Growing Market for Vehicle Tech Upgrades in 2025

The automotive market in 2025 is defined by one clear trend: more drivers are upgrading the cars they already own rather than purchasing new models. Rising prices for new vehicles and limited availability of dealer inventory have pushed consumers to explore aftermarket solutions that deliver the same conveniences at a fraction of the cost.

This shift has created explosive growth in the car technology upgrade sector. Drivers are searching for ways to bring streaming, navigation, and voice control into older cars that are still reliable on the road. Products like Drivio Play have become central to this expansion by offering an accessible bridge between traditional vehicles and modern digital features.

Industry data reflects this momentum. Online searches for terms like “car infotainment upgrade,” “wireless driving tech,” and “retrofit vehicle display” have climbed steadily throughout 2025. Forums, social media groups, and review platforms consistently feature discussions about devices that make older cars feel new again. Drivio Play is often mentioned in these conversations as a leading example of affordable innovation.

Consumer behavior also shows that drivers prefer flexible, portable solutions over permanent installations. With families sharing cars, commuters leasing vehicles, and travelers using rentals, adaptability has become as important as functionality. Drivio Play aligns with this trend by offering portability without compromising performance.

The rapid growth of this market signals a long-term change in how consumers think about car ownership. Instead of relying on dealerships for upgrades, they are turning to independent solutions that combine affordability with control. Drivio Play sits at the center of this new movement, showing how everyday drivers are shaping the future of automotive technology.

See why the vehicle tech upgrade market is growing with Drivio Play

Real-World Experiences and Consumer Feedback

The most persuasive insights about any product often come from everyday users. In 2025, Drivio Play has attracted attention across forums, social platforms, and review sites where drivers share how the system has impacted their daily commutes and long-distance travel.

Many reviews highlight ease of installation as a standout feature. Drivers note that they were able to set up the device quickly without paying dealership labor costs. This user-friendly design has made it especially popular with households that want results without technical headaches.

Clarity of the display is another recurring theme. Commuters appreciate the crisp visuals when navigating busy streets or long highway stretches, while families point out that the sharp screen makes trip planning smoother and safer. Positive feedback often emphasizes that the clear interface reduces stress behind the wheel.

Hands-free functionality is also praised. Users report that calls and voice commands work smoothly, allowing them to stay connected without fumbling with a phone. For many, this convenience doubles as a safety upgrade, aligning with modern expectations for distraction-free driving.

Of course, not all reviews are the same. Some drivers note that no aftermarket system can replace the full integration of high-end dealership upgrades. These comments typically suggest setting realistic expectations—understanding that Drivio Play is built for affordability and flexibility, not luxury exclusivity. Yet even these balanced perspectives reinforce the value of the device as a practical, budget-friendly alternative.

What unites most user feedback is satisfaction with the balance of price and performance. Drivio Play is frequently described as a solution that makes older vehicles feel modern again without the cost of a trade-in. This perception has fueled ongoing conversations and positioned it as one of the standout aftermarket solutions of 2025.

Read real-world feedback and experiences with Drivio Play here

Why 2025 Is the Right Time to Upgrade With Drivio Play

The decision to modernize an older vehicle often comes down to timing. In 2025, that timing could not be better. Rising car prices, longer loan terms, and the ongoing cost of ownership have forced many drivers to rethink whether buying new is the smartest choice. Instead, upgrading with affordable tech has become the more logical path forward.

Drivio Play is positioned perfectly within this shift. It allows households to enjoy premium features like real-time navigation, streaming, and voice-command functionality without trading in a vehicle that still performs well. For families balancing financial caution with modern expectations, this device is a straightforward solution.

Another factor is lifestyle change. More commuters are back on the road, and road trips have surged as families choose driving over costly flights. With people spending more time behind the wheel, the demand for convenient, connected, and safe driving tools is higher than ever. Drivio Play answers this demand with a system that installs quickly and enhances any journey.

Technology adoption is also a reason 2025 is the right time. Portable, wireless devices are now a standard part of everyday life, and drivers expect the same ease of use in their vehicles. Drivio Play leverages these trends, making advanced driving tech accessible through a familiar, intuitive design.

With affordability, accessibility, and adaptability aligned, the market momentum suggests that this year is the ideal time for drivers to upgrade their vehicles without financial strain. Drivio Play delivers modern features when they are needed most—right now.

Market Outlook and the Future of Retrofit Car Technology

The retrofit car technology market is entering a new phase in 2025. As drivers hold onto their vehicles longer, demand for affordable upgrades has accelerated. Instead of replacing a car every few years, households are investing in devices that extend functionality and align with modern expectations. This shift is creating strong growth for aftermarket solutions like Drivio Play.

Industry forecasts indicate that retrofit technology will continue expanding over the next five years. Rising car prices, combined with consumer reluctance to take on large loans, point to sustained interest in cost-effective upgrades. Products that add value without requiring professional installation will lead this movement.

Drivio Play reflects the qualities that analysts highlight as drivers of growth: affordability, portability, and compatibility with both iOS and Android systems. By giving households a way to keep older vehicles relevant, it positions itself within a consumer market that is expected to expand steadily as adoption becomes mainstream.

Cultural momentum also plays a role in shaping the outlook. Online forums, auto review sites, and consumer tech discussions increasingly feature conversations about extending vehicle life rather than replacing it. This cultural shift toward sustainability and financial caution reinforces why retrofit solutions resonate with today’s drivers.

The broader future of this niche suggests that products combining convenience, safety, and entertainment will dominate. Drivio Play aligns with this direction, providing a model for how car technology can evolve outside dealership channels.

For drivers, this means greater choice, more control, and access to features that make cars smarter without breaking household budgets. For the industry, it means sustained growth as retrofit solutions become standard in everyday driving.

Final Thoughts and Consumer Takeaway

Drivers are redefining what it means to upgrade their vehicles in 2025. Rather than trading in reliable cars for expensive new models, more households are turning to retrofit solutions that add modern features without overwhelming costs. Drivio Play has emerged as one of the most talked-about devices in this category, offering a blend of affordability, convenience, and compatibility that resonates with everyday drivers.

From families looking for safer commutes, to commuters seeking efficiency, to tech adopters wanting smarter features in older vehicles, Drivio Play delivers practical solutions. Its portability, hands-free functionality, navigation support, and easy installation make it a device that fits multiple lifestyles and budgets.

The broader market confirms this trend. Retrofit technology is no longer an afterthought—it is becoming the mainstream choice for consumers who want to extend vehicle value. By focusing on affordability and usability, Drivio Play reflects the direction of the entire automotive upgrade sector.

For consumers evaluating their options in 2025, the takeaway is simple: upgrading your current car does not have to be costly or complicated. Drivio Play provides an accessible path to smarter, safer, and more enjoyable driving without dealership prices.

Get started with Drivio Play today

Contact

• Company: DrivoPlay– Supporting smarter consumer solutions in 2025

• Email: support@drivioplay.com

• Phone (US): +1 (888) 458-0473

Final Disclaimer

This press release is for informational purposes only. The content herein does not constitute financial, legal, medical, or professional advice. Drivio Play is not intended to diagnose, treat, predict, or guarantee any result or outcome. Individual experiences may vary, and outcomes are not assured.

Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication.

All statements made about product features, consumer strategies, or technology outlook reflect publicly available information, user discussions, or historical trends, and are not endorsed or validated by regulatory bodies. Readers are encouraged to perform their own research before making financial, technological, or purchasing decisions.

CONTACT: Email: support@drivioplay.com Phone (US): +1 (888) 458-0473

DELRAY BEACH, Fla.  , Aug. 23, 2025 /PRNewswire/ — The global Targeted Protein Degradation Market, valued at US$0.01 billion in 2024, stood at US$0.48 billion in 2025 and is projected to advance at a resilient CAGR of 35.4% from 2025 to 2035, culminating in a forecasted valuation of US$9.85 billion by the end of the period. This is mainly due to various factors such as Priority/Fast Track designations and expected first-in-class approvals & and multi-indication expansion. However, the CMC & scale-up complexity for heterobifunctional & IP disputes are predicted to cause market growth barriers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219352281

Browse in-depth TOC on “Targeted Protein Degradation Market“

380 – Tables
60 – Figures
402 – Pages

By formulation, the global targeted protein degradation market is segmented by formulation into two main categories: oral and injections. In 2024, the oral formulations segment holds the highest share in the formulation landscape of the novel TPD market, driven by its favorable pharmacokinetics, patient compliance, and manufacturing scalability. Oral delivery remains the preferred route due to its non-invasive nature and ease of administration, which significantly enhances patient adherence, especially in chronic or long-term treatments. The advancements in medicinal chemistry have enabled the development of orally bioavailable degraders, overcoming early limitations of poor solubility and permeability. Many first-generation PROTACs faced challenges with oral bioavailability due to their large molecular weight and polarity; however, recent innovation in structural optimization has yielded degrader candidates suitable for oral dosing without compromising efficacy. From a commercial perspective, oral formulations offer cost-efficiency in distribution and storage, adding to their attractiveness. Oral TPD candidates in oncology, immunology, and neurology have shown promising clinical progress, reinforcing confidence in this route. As the TPD field matures, oral formulations are expected to dominate clinical pipelines and product launches, setting the standard for patient-friendly, scalable therapeutic solutions. The continued investment in optimizing oral bioavailability across heterobifunctional and molecular glue degraders is anticipated to fuel segment growth.

By Type, the PROTACs (PROteolysis TArgeting Chimeras) segment was the fastest-growing within the targeted protein degradation (TPD) market due to their ability to selectively eliminate, rather than inhibit, disease-causing proteins. By leveraging the natural ubiquitin-proteasome system of cells, PROTACs redirect E3 ligases to tag specific proteins for degradation, offering a novel approach to address previously undruggable targets. Unlike conventional inhibitors, PROTACs can achieve greater potency and sustained therapeutic effects, often requiring lower doses and showing potential to overcome resistance mechanisms. This has sparked intense interest from the pharmaceutical industry, leading to a rapidly expanding pipeline with numerous candidates advancing through preclinical and clinical development. Clinical-stage PROTACs like ARV-471, ARV-110, and NX-2127 are being evaluated in oncology, particularly in hormone-driven cancers. Ongoing innovation in linker chemistry, E3 ligase selection, and optimization for oral delivery is driving improvements in drug-like properties. With increasing investments, strategic collaborations, and a broadening scope across therapeutic areas, PROTACs are poised to become a cornerstone of next-generation drug discovery. Their versatility and ability to precisely degrade specific proteins continue to position them as a leading modality within the growing TPD market.

By geography, the market for targeted protein degradation is divided into six segments: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share in the targeted protein degradation (TPD) market, driven by strong R&D infrastructure, robust funding ecosystems, and a favorable regulatory environment. The region is home to several pioneering biotechnology and pharmaceutical companies that are leading the development of TPD platforms, particularly PROTACs and molecular glues. Major players such as Arvinas, C4 Therapeutics, and Nurix Therapeutics are headquartered in the US, benefiting from access to top-tier research institutions and a highly skilled scientific workforce. In addition, consistent capital inflow from venture capital firms, public markets, and strategic pharmaceutical partnerships has accelerated innovation and clinical progression of TPD candidates. The US Food and Drug Administration (FDA) has also played a critical role by granting fast track and orphan drug designations to promising TPD candidates, thereby expediting their development and regulatory pathways. Increasing investment in oncology, neurodegenerative diseases, and autoimmune indications, which are the key therapeutic areas for TPDs, will continue to drive demand in the region. Academic-industry collaborations, the presence of large-scale clinical trial networks, and a strong intellectual property framework further enhance the leadership position of North America. These combined factors position the region to achieve the highest growth trajectory in the global TPD market.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=219352281

Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer (Vividion) (Germany), Captor Therapeutics (Poland), Ranok Therapeutics (US), Pfizer (US), Novartis (Switzerland), and Foghorn Therapeutics (US).

Bristol Myers Squibb:

Bristol Myers Squibb (BMS) is a key player in the targeted protein degradation (TPD) market, leveraging its extensive drug development capabilities to advance next-generation therapeutics. BMS was among the earliest large pharmaceutical companies to recognize the potential of TPD, particularly through molecular glues that reprogram E3 ligases to degrade disease-causing proteins. The company inherited significant TPD assets and expertise by acquiring Celgene, including its partnership with Evotec and initial collaborations with startups such as C4 Therapeutics. BMS continues to build a robust pipeline of TPD candidates, especially in oncology and immunology, where traditional small molecules or biologics have limited efficacy. Its approach combines in-house discovery with strategic partnerships to broaden target scope and accelerate clinical progression. With ongoing investments in E3 ligase biology and protein degradation mechanisms, BMS is positioning itself as a long-term leader in the TPD space. Its focus on molecular glues and degrader programs highlights a commitment to expanding and offering new therapeutic avenues for complex diseases.

Arvinas:

Arvinas is a pioneer in the targeted protein degradation (TPD) field, recognized for being the first company to bring a PROTAC (PROteolysis TArgeting Chimera) degrader into clinical trials. Founded on technology from Yale University, Arvinas has developed a proprietary platform that harnesses the ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its clinical pipeline includes ARV-110 and ARV-471, which target androgen and estrogen receptors in prostate and breast cancers, respectively. Its strong scientific foundation and first-mover advantage have positioned it as a leader in the TPD space. In addition to internal programs, Arvinas has formed high-profile collaborations with Pfizer and Bayer, leveraging its platform to explore new targets and therapeutic areas beyond oncology. These partnerships validate its technology and provide significant funding and development support. As the TPD field matures, Arvinas stands out for its clinical progress, strategic alliances, and expanding expertise in rational degrader design, which could lead to transformative therapies for patients with limited treatment options.

For more information, Inquire Now!

Related Reports:

Pharmaceutical Drug Delivery Market

Active Pharmaceutical Ingredient Market

Pharmaceutical Contract Manufacturing Market

Drug Discovery Services Market

Pharmaceutical Excipients Market 

Get access to the latest updates on Targeted Protein Degradation Companies and Targeted Protein Degradation Market Size

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

A novel blood test could make it easier to diagnose and monitor multiple myeloma (MM), according to the investigators behind the research. The findings were recently published in the journal Nature Cancer.¹ 

The SWIFT-seq method, which employs single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, could offer a noninvasive alternative to traditional bone marrow biopsies.

“A lot of work has gone into the identification of genomic and transcriptomic features that predict worse outcome in MM, but we are still lacking the tests to measure them in our patients,” senior author Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, said in a press release.² “As a clinician, this is the type of next-generation test that I would want to order for my patients.”

Ghobrial and colleagues explained that bone marrow (BM) biopsies are the primary method of staging and restaging patients with MM or its precursors, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).¹ However, such biopsies are invasive and painful, which is why they are rarely used for continuous monitoring of patients.

“Additionally, MM is a partially heterogeneous disease, where a single-site BM biopsy may not provide comprehensive information on tumor burden and disease biology occurring throughout the body,” they wrote.

Fluorescence in situ hybridization (FISH) is an accompanying technique that can be used for risk stratification in MM and SMM. However, the technique requires a BM biopsy, and its sensitivity is limited.

Ghobrial and colleagues wanted to see whether there was a more effective—and less invasive—means of diagnosing and monitoring MM. They focused on CTCs, which can be detected in the peripheral blood of patients with MM and its precursors, and their quantification has been shown to have prognostic value. One study found that patients with high levels of CTCs were more likely to have aggressive disease than those with lower CTC levels.³

In the new report, Ghobrial and colleagues outline a new method of assessing CTCs in the blood.¹ The system, called SWIFT-seq, uses single-cell sequencing to profile CTCs in the blood. The system means that clinicians can monitor patients with MM using a simple blood test instead of the more invasive BM biopsy.

SWIFT-seq is capable of quantifying CTCs, but it can also do more than that, and with a higher degree of accuracy than FISH, the authors said. 

“SWIFT-seq is a powerful option as it can measure the number of CTCs, characterize the genomic alterations of the tumor, estimate the tumor’s proliferative capacity, and measure prognostically useful gene signatures in a single test and from a blood sample,” Ghobrial said in the accompanying press release.²

To develop the method, the investigators studied 101 patients and healthy donors. They found that SWIFT-seq was able to successfully capture CTCs in 90% of patients with MGUS, SMM, and MM, including in 95% of patients with SMM and 94% of patients with newly diagnosed MM.¹ Ghobrial and colleagues noted that these patients are those most likely to benefit from improved risk stratification and genomic surveillance.

“We identified a gene signature that we believe captures the tumor’s circulatory capacity and may partly explain some of the unexplained mysteries of myeloma biology,” Elizabeth D. Lightbody, PhD, co-first author, said in a statement.² “This can have a tremendous impact in how we think about curtailing tumor spread in patients with myeloma and could lead to the development of new drugs for patients.”

The investigators said under the current paradigm, it would take 4 separate assays (including FISH) to obtain the same level of characterization. Three of those assays require a BM biopsy, they noted.¹

They said they believe SWIFT-seq could be “pivotal” for advancing blood-test tumor profiling for patients with MM.

“It would be amazing if we had a blood-based test that can outperform FISH and that works in the majority of patients—we think SWIFT-seq may just be that test,” Romanos Sklavenitis-Pistofidis, MD, PhD, co-first author, said.²

References

1. Lightbody ED, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nat Cancer. Published online August 8, 2025. doi:10.1038/s43018-025-01006-0

2. Dana-Farber Cancer Institute unveils groundbreaking blood test for multiple myeloma. News release. Dana-Farber Cancer Institute. August 8, 2025. Accessed August 22, 2025. https://www.dana-farber.org/newsroom/news-releases/2025/dana-farber-cancer-institute-unveils-groundbreaking-blood-test-for-multiple-myeloma

3. Bertamini L, Oliva S, Rota-Scalabrini D, et al. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2022;40(27):3120-3131. doi:10.1200/JCO.21.01393